



Nova Leap Health Corp.

**Unaudited Condensed Interim Consolidated Financial Statements
For the three and six months ended June 30, 2024 and 2023**

(United States dollars)

Nova Leap Health Corp.

Unaudited Condensed Interim Consolidated Statements of Financial Position

(United States dollars)

As at	June 30, 2024	December 31, 2023
	\$	\$
ASSETS		
Current assets		
Cash and cash equivalents	1,165,368	894,765
Accounts receivable	1,520,869	1,652,116
Prepaid expenses	428,576	294,248
Total current assets	3,114,813	2,841,129
Non-current assets		
Property and equipment	1,066,310	1,188,383
Intangible assets	491,694	542,711
Goodwill (note 4)	14,762,255	14,622,219
Deferred income tax asset	1,542,563	1,701,285
Total non-current assets	17,862,822	18,054,598
TOTAL ASSETS	20,977,635	20,895,727
LIABILITIES		
Current liabilities		
Accounts payable and accrued liabilities	1,349,552	1,240,953
Client deposits payable	48,299	59,584
Promissory notes (note 6)	144,899	117,509
Lease liability	288,854	276,124
Government loans	-	90,730
Total current liabilities	1,831,604	1,784,900
Non-current liabilities		
Promissory notes (note 6)	24,070	-
Lease liability	795,714	914,056
Total non-current liabilities	819,784	914,056
TOTAL LIABILITIES	2,651,388	2,698,956
SHAREHOLDERS' EQUITY		
Share capital (note 7)	18,959,250	18,959,250
Contributed surplus	2,309,331	2,263,219
Accumulated other comprehensive loss	(1,394,942)	(778,235)
Deficit	(1,547,392)	(2,247,463)
TOTAL SHAREHOLDERS' EQUITY	18,326,247	18,196,771
TOTAL LIABILITIES AND SHAREHOLDERS' EQUITY	20,977,635	20,895,727

The accompanying notes form an integral part of these unaudited condensed interim consolidated financial statements.

Approved on behalf of the Board of Directors

“Michael O’Keefe”

(signed)

Director

“Chris Dobbin”

(signed)

Director

Nova Leap Health Corp.

Unaudited Condensed Interim Consolidated Statements of Income (Loss) and Comprehensive Income (Loss)

(United States dollars)

For the	Three months ended June 30		Six months ended June 30	
	2024	2023	2024	2023
	\$	\$	\$	\$
Revenues				
Service revenues	6,338,532	6,677,360	12,768,253	13,073,436
Operating expenses				
Cost of service	3,902,837	4,217,841	7,889,577	8,361,961
	2,435,695	2,459,519	4,878,676	4,711,475
Corporate and administrative expenses				
Head office and operations management	1,489,815	1,525,981	3,080,613	3,158,456
General & administrative	537,984	547,454	1,028,365	1,080,910
Amortization and depreciation	138,893	256,835	289,168	490,862
Stock-based compensation	21,294	12,587	46,112	47,449
	2,187,986	2,342,857	4,444,258	4,777,677
Income (loss) from operating activities	247,709	116,662	434,418	(66,202)
Other income (expenses)				
Foreign exchange gain (loss)	153,433	(353,657)	525,300	(365,404)
Forgiveness of government loans	-	-	29,544	-
Impairment loss (note 4)	-	(350,567)	-	(350,567)
Finance expense	(21,906)	(23,358)	(43,195)	(92,813)
Litigation settlement gain (note 8)	-	352,789	-	352,789
Acquisition related and other legal expenses	(54,438)	(11,769)	(54,754)	(118,260)
Other expenses	(6,195)	(7,064)	(12,401)	(9,245)
	70,894	(393,626)	444,494	(583,500)
Income (loss) before income taxes	318,603	(276,964)	878,912	(649,702)
Income taxes				
Deferred income tax (expense) recovery	(81,730)	102,005	(159,091)	186,557
Current income tax expense	(9,875)	(8,542)	(19,750)	(17,232)
	(91,605)	93,463	(178,841)	169,325
Net Income (loss)	226,998	(183,501)	700,071	(480,377)
Items that will be reclassified subsequently to profit or loss				
Foreign exchange (loss) gain on translation to presentation currency	(180,906)	396,794	(616,707)	410,928
Total comprehensive income (loss)	46,092	213,293	83,364	(69,449)
Net income (loss) per share – basic and diluted (note 9)	\$0.003	\$(0.002)	\$0.008	\$(0.006)

The accompanying notes form an integral part of these unaudited condensed interim consolidated financial statements.

Nova Leap Health Corp.

Unaudited Condensed Interim Consolidated Statements of Changes in Shareholders' Equity

(United States dollars)

	Common shares	Share capital \$	Contributed surplus \$	Accumulated other comprehensive (loss) income \$	Deficit \$	Total shareholders' equity \$
Balance at January 1, 2024	86,209,252	18,959,250	2,263,219	(778,235)	(2,247,463)	18,196,771
Stock-based compensation	-	-	46,112	-	-	46,112
Net income for the period	-	-	-	-	700,071	700,071
Other comprehensive loss for the period	-	-	-	(616,707)	-	(616,707)
Balance at June 30, 2024	86,209,252	18,959,250	2,309,331	(1,394,942)	(1,547,392)	18,326,247
Balance at January 1, 2023	86,209,252	18,959,250	2,130,911	(1,215,458)	(1,192,782)	18,681,921
Stock-based compensation	-	-	47,449	-	-	47,449
Net loss for the period	-	-	-	-	(480,377)	(480,377)
Other comprehensive income for the period	-	-	-	410,928	-	410,928
Balance at June 30, 2023	86,209,252	18,959,250	2,178,360	(804,530)	(1,673,159)	18,659,921

The accompanying notes form an integral part of these unaudited condensed interim consolidated financial statements.

Nova Leap Health Corp.

Unaudited Condensed Interim Consolidated Statements of Cash Flows

(United States dollars)

For the	Three months ended June 30		Six months ended June 30	
	2024	2023	2024	2023
	\$	\$	\$	\$
Cash provided by (used in)				
Operating activities				
Net income (loss) for the period	226,998	(183,501)	700,071	(480,377)
Government tax credit receivable	-	452,306	-	659,495
Adjustments for items not affecting cash:				
Forgiveness of promissory notes on litigation settlement (note 8)	-	(257,789)	-	(257,789)
Amortization and depreciation	138,893	256,835	289,168	490,862
Impairment loss (note 4)	-	350,567	-	350,567
Deferred income tax expense (recovery)	81,730	(102,005)	159,091	(186,557)
Stock-based compensation	21,294	12,587	46,112	47,449
Finance expense	19,814	49,810	39,269	122,823
Unrealized foreign exchange (gain) loss	(159,751)	345,249	(536,387)	357,303
Forgiveness of government loans	-	-	(29,544)	-
Gain on the sale of assets	-	-	-	(4,861)
Net change in non-cash operating working capital (note 10)	58,731	(259,374)	94,233	(139,903)
Cash provided by operating activities	387,709	664,685	762,013	959,012
Investing activities				
Acquisition of business (note 3)	(250,000)	-	(250,000)	-
Purchase of property and equipment	-	-	-	(27,990)
Proceeds on the sale of assets	-	-	-	4,861
Cash used in investing activities	(250,000)	-	(250,000)	(23,129)
Financing activities				
Repayment of demand loans and transaction costs (note 5)	-	(553,866)	-	(946,500)
Repayment of government loans	-	-	(59,333)	-
Interest payments on demand loans (note 5)	-	(15,871)	-	(41,764)
Repayment of promissory notes and interest (note 6)	-	-	-	(127,500)
Repayment of lease liability and interest	(90,529)	(104,675)	(178,899)	(208,816)
Cash used in financing activities	(90,529)	(674,412)	(238,232)	(1,324,580)
Effect of foreign exchange rate change on cash and cash equivalents	1,426	3,619	(3,178)	4,308
Increase (decrease) in cash and cash equivalents for the period	48,606	(6,108)	270,603	(384,389)
Cash and cash equivalents - beginning of period	1,116,762	894,365	894,765	1,272,646
Cash and cash equivalents - end of period	1,165,368	888,257	1,165,368	888,257

Nova Leap Health Corp.

Notes to the Unaudited Condensed Interim Consolidated Financial Statements

(United States dollars)

For the three and six months ended June 30, 2024 and 2023

1. Nature of operations

Nova Leap Health Corp. (the “Corporation”) is the parent company and was incorporated under the Canada Business Corporations Act on November 16, 2015. The principal activities of the Corporation and its subsidiaries (the “Group”) is to provide home and home health care services to clients. The Group is currently providing services in the United States in ten states as well as in Nova Scotia, Canada. The Corporation’s shares are listed on the TSX Venture Exchange and are traded under the symbol NLH and the over-the-counter market (OTCBB) in the United States under the symbol NVLPF.

These Unaudited Condensed Interim Consolidated Financial Statements include the accounts of the Corporation and its United States (“US”) and Canadian subsidiaries and are presented in United States dollars (“USD”) which is the functional currency of the majority of the Group’s business operations. The registered head office of the Corporation is located at 7071 Bayers Road, Suite 3006, Halifax, NS Canada B3L 2C2.

The Unaudited Condensed Interim Consolidated Financial Statements were approved by the Board of Directors on August 8, 2024.

2. Material accounting policies

Statement of compliance

These Unaudited Condensed Interim Consolidated Financial Statements are prepared in accordance with IAS 34, *Interim Financial Reporting* as issued by the International Accounting Standards Board (“IASB”). These Unaudited Condensed Interim Consolidated Financial Statements were prepared using the same accounting policies and methods of computation and are subject to the same use of estimates and judgments as the Corporation’s Audited Consolidated Financial Statements for the year ended December 31, 2023. These Unaudited Condensed Interim Consolidated Financial Statements do not include all disclosures required by IFRS Accounting Standards as issued by the International Accounting Standards Board (“IFRS Accounting Standards”) for annual consolidated financial statements and accordingly should be read in conjunction with the Corporation’s Audited Consolidated Financial Statements for the year ended December 31, 2023, prepared in accordance with IFRS Accounting Standards.

3. Business acquisitions

On May 3, 2024, the Corporation acquired a home care business located in Massachusetts. The acquisition was made for total consideration of \$300,000 of which \$250,000 was payable with cash on closing and \$50,000 by way of a promissory note repayable over a two-year period. The details of the business acquisition is as follows:

	Massachusetts
Acquisition date	May 3, 2024
	\$
Acquisition costs	54,754
Fair value of consideration transferred	
Cash	250,000
Promissory note to vendor	46,067
Total	296,067
Recognized amounts of identifiable net assets	
Intangible assets - customer lists	30,000
Intangible assets - non-compete agreements	50,000
Goodwill	216,067
Total	296,067
Contribution to Group Results	
Revenue from date of acquisition to reporting date	146,585

Nova Leap Health Corp.

Notes to the Unaudited Condensed Interim Consolidated Financial Statements

(United States dollars)

For the three and six months ended June 30, 2024 and 2023

3. Business acquisitions (continued)

Operating loss from date of acquisition to reporting date (including non-cash amortization and depreciation of \$6,672)	(3,823)
-------------------------------------------------------------------------------------------------------------------------	---------

Goodwill

Goodwill is primarily related to growth expectations, expected future profitability and the assembled workforce.

Proforma Group Results and Other

Proforma Group results based on acquiring the assets of all closed acquisitions at January 1, 2024

If the assets of the businesses acquired during the period had been acquired on January 1, 2024, revenue of the Group for the six months ended June 30, 2024 would have increased by approximately \$315,000 and income from operating activities would have decreased by approximately \$8,000, including \$14,000 of non-cash amortization expense

4. Goodwill

During the quarter ended June 30, 2023, the Corporation determined that indicators of impairment exist within the US-RI CGU and a goodwill impairment test was completed which resulted in an impairment loss of \$350,567 for the three and six months ended June 30, 2023. The impairment loss was due to a decline in client service hours and an expected longer recovery time to return to previous revenue levels.

At December 31, 2023, due to a continued decline in client service hours, an additional goodwill impairment test was completed which resulted in an impairment of \$1,151,995. The total impairment losses recognized related to the US-RI CGU for the year ended December 31, 2023 was \$1,502,562.

5. Demand loans

The changes in the demand loans for the period are as follows:

	June 30, 2024	December 31, 2023
	\$	\$
At amortized cost:		
Balance, beginning of period	-	1,378,244
Debt issue and guarantee insurance costs	-	(6,515)
Effective interest	-	47,452
Interest payments	-	(55,817)
Principal repayment in cash	-	(1,369,521)
Foreign exchange loss	-	6,157
Balance, end of period	-	-
Fair value	-	-

At December 31, 2023, all demand loans were fully repaid.

The Corporation also has access to a \$1,095,930 (CAD\$1,500,000) revolving operating facility for working capital purposes from a Schedule 1 Canadian bank. The interest rate is the CAD prime rate plus 1.5%. The CAD prime rate at June 30, 2024 was 6.95% (December 31, 2023 – 7.20%). Interest is calculated monthly in arrears, and payable on the last day of each month. The facility is repayable on demand. There was no outstanding balance on this facility as at June 30, 2024 or December 31, 2023.

All the demand loans were secured through a registered General Security Agreement and a Corporate Guarantee for the principal amount of the loan from Nova Leap's US and Canadian subsidiaries.

Nova Leap Health Corp.

Notes to the Unaudited Condensed Interim Consolidated Financial Statements

(United States dollars)

For the three and six months ended June 30, 2024 and 2023

6. Promissory notes

The changes in the promissory notes for the period are as follows:

	June 30, 2024	December 31, 2023
	\$	\$
Balance, beginning of period	117,509	1,008,035
Issuance of promissory notes for acquisition of business (note 3)	46,067	-
Effective interest	5,393	49,763
Repayments	-	(682,500)
Forgiveness of notes on litigation settlement (note 8)	-	(257,789)
Balance, end of period	168,969	117,509
Current portion	144,899	117,509
Non-current portion	24,070	-
Balance, end of period	168,969	117,509
Fair value	166,851	119,940

The promissory notes were all initially recorded at fair value using market interest rates ranging between 7.75% and 10.5% and subsequently measured at amortized cost using the effective interest rate method.

The promissory notes are subject to a Guarantee Agreement from the Corporation and are subordinated to the demand loans (note 5).

7. Share capital

a. Authorized:

Unlimited number of common shares, without nominal or par value.

b. Issued and outstanding:

	June 30, 2024		December 31, 2023	
	Number of Shares	Cost \$	Number of Shares	Cost \$
Balance, beginning and end of period	86,209,252	18,959,250	86,209,252	18,959,250

8. Litigation settlement

The litigation previously initiated by Nova Leap in Q2 2022 was settled during the three months ended June 30, 2023, resulting in a total gain of \$352,789. The settlement consisted of Nova Leap receiving a cash payment of \$95,000, forgiveness of the remaining promissory notes plus accrued interest of \$257,789 and the elimination of any future earnout payments.

Nova Leap Health Corp.

Notes to the Unaudited Condensed Interim Consolidated Financial Statements

(United States dollars)

For the three and six months ended June 30, 2024 and 2023

9. Earnings per share

Basic earnings per share is calculated based on the weighted average number of shares outstanding during the period. Diluted earnings per share assumes that stock options and DSUs have been exercised on the later of the beginning of the period and the date granted. For the three and six months ended June 30, 2024, 5,362,500 options were excluded from the computation of diluted earnings per share because their effect would have been anti-dilutive. For the three and six months ended June 30, 2023 all stock options and DSUs were excluded from the computation of diluted income per share because their effect would have been anti-dilutive.

The following table summarizes the basic and diluted weighted average number of shares:

	Three months ended June 30		Six months ended June 30	
	2024	2023	2024	2023
Weighted average number of shares used in basic earnings per share	86,209,252	86,209,252	86,209,252	86,209,252
Shares deemed to be issued for no consideration in respect of share-based payments	1,319,040	-	1,205,657	-
Weighted average number of shares used in basic and diluted earnings per share	87,528,292	86,209,252	87,414,909	86,209,252

10. Supplemental cash flow information

The change in the non-cash operating working capital is as follows:

	Three months ended June 30		Six months ended June 30	
	2024	2023	2024	2023
	\$	\$	\$	\$
Accounts receivable	46,891	(42,302)	131,247	80,298
Prepaid expenses	(86,994)	(56,459)	(134,328)	(104,372)
Accounts payable and accrued liabilities	107,208	(163,238)	108,599	(119,375)
Client deposits payable	(8,374)	2,625	(11,285)	3,546
	58,731	(259,374)	94,233	(139,903)
Supplemental information:				
Interest paid	16,669	35,298	33,875	84,236
Income taxes paid	40,834	6,400	40,834	7,090

11. Related party transactions

Transactions with related parties are in the normal course of operations and are measured at the exchange amount, which is the amount agreed to by the parties. Related parties include members of the Board of Directors, as well as the Chief Executive Officer and the Chief Financial Officer.

Nova Leap Health Corp.

Notes to the Unaudited Condensed Interim Consolidated Financial Statements

(United States dollars)

For the three and six months ended June 30, 2024 and 2023

11. Related party transactions (continued)

Corporate and administrative expenses include the following related party remuneration expenses:

	Three months ended June 30		Six months ended June 30	
	2024	2023	2024	2023
	\$	\$	\$	\$
Management compensation	109,802	98,652	228,609	204,053
Directors' compensation	35,078	35,738	70,665	71,242
Stock-based compensation	22,212	27,805	44,363	54,487
	167,092	162,195	343,637	329,782

As at June 30, 2024, there was \$40,107 included in accounts payable and accrued liabilities for amounts owed to officers of the Corporation for compensation and expense reimbursements (December 31, 2023 – \$53,337) and \$10,959 for amounts due to directors for directors fees (December 31, 2023 – \$11,341).

12. Financial instruments

The Group's risk management is coordinated at its Head Office, in close cooperation with the Board of Directors, and focuses on actively securing the Group's short to medium-term cash flows by maximizing cash flow from operations.

The Group is exposed to various risks in relation to financial instruments. The main types of risks are credit risk, liquidity risk and market risk. The Group is exposed to the same risks in the current year as it was exposed to in the prior year. The most significant financial risks to which the Group is exposed are described below.

Credit risk

Credit risk is the risk that a counterparty fails to discharge an obligation to the Group. The Group is exposed to this risk for various financial instruments, for example by granting receivables to customers and placing deposits.

The Group's maximum exposure to credit risk is limited to the carrying amount of financial assets recognized at the end of the reporting period, as summarized below:

Classes of financial assets – carrying amounts	June 30, 2024	December 31, 2023
	\$	\$
Cash and cash equivalents	1,165,368	894,765
Accounts receivable	1,520,869	1,652,116
	2,686,237	2,546,881

Credit risk management

The credit risk is managed on a group basis based on the Group's credit risk management policies and procedures. The credit risk in respect of cash balances held with banks is managed by only using major reputable financial institutions.

The Group does not specifically assess the credit quality of clients based on a credit rating but through an informal process while onboarding for service. Invoice terms are generally payable within thirty days. The ongoing credit risk is managed through regular review of the aging analysis.

At certain locations, clients are required to pay an upfront deposit, mitigating the credit risk. As at June 30, 2024, the Group had \$48,299 collected for client deposits (December 31, 2023 - \$59,584), representing approximately 3.2% of outstanding accounts receivable, billed and accrued (December 31, 2023 – 3.6%).

Nova Leap Health Corp.

Notes to the Unaudited Condensed Interim Consolidated Financial Statements

(United States dollars)

For the three and six months ended June 30, 2024 and 2023

12. Financial instruments (continued)

Liquidity risk

Liquidity risk is the risk that the Group might be unable to meet its obligations. The Group manages its liquidity needs by monitoring scheduled debt servicing payments for long-term financial liabilities as well as forecasting cash inflows and outflows due in day-to-day business. The data used for analysing these cash flows is consistent with that used in the contractual maturity analysis below.

Liquidity needs are monitored in various time bands, on a day-to-day and week-to-week basis, as well as on the basis of a rolling 30-day projection. Long-term liquidity needs for a quarterly lookout period are identified monthly. Net cash requirements are compared to available cash balances and available borrowing facilities in order to determine headroom or shortfalls. This analysis shows that available borrowing facilities and available cash are expected to be sufficient for the next twelve months.

The Group considers expected cash flows from financial assets in assessing and managing liquidity risk, in particular its cash resources and accounts receivable. The Group's existing cash resources and accounts receivable, in addition to the current unused balance of the revolving operating facility and cash flow projections, are expected to be sufficient to meet current contractual cash outflow requirements. Cash flows from accounts and other receivables are all contractually due within 30 days.

The Group's financial liabilities have contractual maturities (including interest payments where applicable) as summarized below:

As at June 30, 2024	< 1 year \$	1-2 years \$	3-5 years \$	> 5 years \$
Accounts payable and accrued liabilities	1,349,552	-	-	-
Client deposits	48,299	-	-	-
Promissory notes, principal and interest	153,500	26,250	-	-
Lease liability, principal and interest	344,495	314,058	376,200	192,874
Total	1,895,846	340,308	376,200	192,874

As at December 31, 2023	< 1 year \$	1-2 years \$	3-5 years \$	> 5 years \$
Accounts payable and accrued liabilities	1,240,953	-	-	-
Client deposits	59,584	-	-	-
Promissory notes, principal and interest	126,000	-	-	-
Lease liability, principal and interest	335,938	305,579	480,096	238,228
Government loans	60,487	-	-	-
Total	1,822,962	305,579	480,096	238,228

Market risk

The Group is exposed to market risk through its use of financial instruments and specifically to currency risk and interest rate risk, which result from both its operating and financing activities.

Foreign currency sensitivity

The Group's operations are carried out in USD. Exposure to currency exchange rates arise from Canadian assets, liabilities, home care operations and head office costs.

Nova Leap Health Corp.

Notes to the Unaudited Condensed Interim Consolidated Financial Statements

(United States dollars)

For the three and six months ended June 30, 2024 and 2023

12. Financial instruments (continued)

The Group's exposure to the Canadian dollar ("CAD") currency risk was as follows:

	June 30, 2024	December 31, 2023
	CAD\$	CAD\$
Cash and cash equivalents	493,058	288,643
Accounts receivable	258,622	232,445
Accounts payable & accrued liabilities	(545,596)	(455,173)
Lease liability	(866,006)	(933,413)
Government loans	-	(120,000)
	(659,922)	(987,498)

A change of 5.0% in the Canadian dollar exchange rate at June 30, 2024 would affect net income and comprehensive income and deficit by approximately \$23,000 (June 30, 2023 - \$39,000).

Interest rate sensitivity

As at June 30, 2024, the Group is not exposed to changes in market interest rates through bank borrowings at variable interest rates. An increase or decrease of 1% in interest rates would have no affect net income and comprehensive income and deficit (June 30, 2023- \$3,000).

Fair value

All financial assets and liabilities except for the promissory notes are short-term. The carrying values of short-term financial assets and liabilities are a reasonable approximation of fair value. The fair value of the promissory notes is disclosed in note 6.

13. Segment reporting

Management identifies the Group's reportable segments as Canadian operations and US operations. All businesses provide home care services to clients. These operating segments are monitored by the Group's Chief Executive Officer and strategic decisions are made based on segment operating results. Group Head Office provides management oversight and expertise including merger and acquisitions services.

Segment information for the reporting period is as follows:

	For the three months ended June 30, 2024				
	US	Canada	Total Reportable Segments	Group Head Office	Total
	\$	\$	\$	\$	\$
Segment revenues	5,353,843	982,230	6,336,073	2,459	6,338,532
Cost of services	3,222,546	680,291	3,902,837	-	3,902,837
Gross margin	2,131,297	301,939	2,433,236	2,459	2,435,695
Corporate & administrative ⁽ⁱ⁾	1,528,298	191,896	1,720,194	307,605	2,027,799
Amortization and depreciation	110,620	12,008	122,628	16,265	138,893
Stock-based compensation	(880)	1,930	1,050	20,244	21,294
Segment operating income (loss)	493,259	96,105	589,364	(341,655)	247,709
Segment assets	17,404,590	2,811,023	20,215,613	762,022	20,977,635

Nova Leap Health Corp.

Notes to the Unaudited Condensed Interim Consolidated Financial Statements

(United States dollars)

For the three and six months ended June 30, 2024 and 2023

13. Segment reporting (continued)

	For the three months ended June 30, 2023				
	US \$	Canada \$	Total Reportable Segments \$	Group Head Office \$	Total \$
Segment revenues	5,763,763	911,182	6,674,945	2,415	6,677,360
Cost of services	3,576,507	641,334	4,217,841	-	4,217,841
Gross margin	2,187,256	269,848	2,457,104	2,415	2,459,519
Corporate & administrative ⁽ⁱ⁾	1,589,363	170,050	1,759,413	314,022	2,073,435
Amortization and depreciation	225,550	14,712	240,262	16,573	256,835
Stock-based compensation	1,549	2,903	4,452	8,135	12,587
Segment operating income (loss)	370,794	82,183	452,977	(336,315)	116,662
Segment assets	18,665,336	2,886,794	21,552,130	830,607	22,382,737

	For the six months ended June 30, 2024				
	US \$	Canada \$	Total Reportable Segments \$	Group Head Office \$	Total \$
Segment revenues	10,863,382	1,899,919	12,763,301	4,952	12,768,253
Cost of services	6,552,709	1,336,868	7,889,577	-	7,889,577
Gross margin	4,310,673	563,051	4,873,724	4,952	4,878,676
Corporate & administrative ⁽ⁱ⁾	3,123,508	378,094	3,501,602	607,376	4,108,978
Amortization and depreciation	232,211	24,191	256,402	32,766	289,168
Stock-based compensation	1,863	3,855	5,718	40,394	46,112
Segment operating income (loss)	953,091	156,911	1,110,002	(675,584)	434,418
Segment assets	17,404,590	2,811,023	20,215,613	762,022	20,977,635

	For the six months ended June 30, 2023				
	US \$	Canada \$	Total Reportable Segments \$	Group Head Office \$	Total \$
Segment revenues	11,249,093	1,819,529	13,068,622	4,814	13,073,436
Cost of services	7,085,327	1,276,634	8,361,961	-	8,361,961
Gross margin	4,163,766	542,895	4,706,661	4,814	4,711,475
Corporate & administrative ⁽ⁱ⁾	3,251,459	342,404	3,593,863	645,503	4,239,366
Amortization and depreciation	427,882	29,944	457,826	33,036	490,862
Stock-based compensation	3,019	5,660	8,679	38,770	47,449
Segment operating income (loss)	481,406	164,887	646,293	(712,495)	(66,202)
Segment assets	18,665,336	2,886,794	21,552,130	830,607	22,382,737

ⁱ⁾ Corporate & administrative includes Head office and operations management expenses and general & administrative expenses.

The Group's revenues from external customers and its non-current assets are all attributable to the U.S. and Canada segments. Revenues from external customers are identified based on the client's geographical location. Non-current assets are allocated based on their physical location.